Get the Stockscreener App
2.875
1.54%
-0.045
Leap Therapeutics Inc stock is traded at $2.875, with a volume of 262.78K.
It is down -1.54% in the last 24 hours and down -3.52% over the past month.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
See More
Previous Close:
$2.92
Open:
$2.92
24h Volume:
262.78K
Relative Volume:
0.75
Market Cap:
$110.16M
Revenue:
$1.50M
Net Income/Loss:
$-81.41M
P/E Ratio:
-0.4416
EPS:
-6.51
Net Cash Flow:
$-43.75M
1W Performance:
-1.20%
1M Performance:
-3.52%
6M Performance:
+46.68%
1Y Performance:
-30.64%
1-Day Range:
$2.72
$2.9325
1-Week Range:
$2.72
$3.07
52-Week Range:
$1.68
$5.00
Leap Therapeutics Inc Stock (LPTX) Company Profile
Name
Leap Therapeutics Inc
Sector
Industry
Phone
617 252 4343
Address
47 THORNDIKE STREET, CAMBRIDGE, MA
Compare LPTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPTX
Leap Therapeutics Inc
|
2.875 | 110.16M | 1.50M | -81.41M | -43.75M | -4.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
402.70 | 103.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
712.33 | 78.28B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
615.00 | 36.77B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.31 | 30.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.95 | 27.32B | 3.30B | -501.07M | 1.03B | -2.1146 |
Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-04-21 | Initiated | Mizuho | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Nov-15-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-13-19 | Resumed | Raymond James | Outperform |
| Mar-07-17 | Initiated | Ladenburg Thalmann | Buy |
View All
Leap Therapeutics Inc Stock (LPTX) Latest News
Gastric Cancer Pipeline, Treatment Drugs, Clinical Trials and Companies 2024 (Updated) - openPR
Leap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest Up 50.7% in December - MarketBeat
HighTower Advisors LLC Makes New $65,000 Investment in Leap Therapeutics, Inc. (NASDAQ:LPTX) - Defense World
Candel Therapeutics Shares Leap on Chairman Purchase - MarketWatch
Biliary Tract Cancer Market Expected to Experience Major Growth by 2034, According to DelveInsight - EIN News
Tonix stock jumps on FDA review for pain drug (TNXP:NASDAQ) - Seeking Alpha
Tenaya stock in selloff on gene therapy data (TNYA:NASDAQ) - Seeking Alpha
Neural Therapeutics Announces Changes to Board of Directors and Completion of Debt Settlement - Yahoo Finance
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference - The Eastern Progress Online
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Stoke Therapeutics' drug 'zorevunersen' earns FDA breakthrough tag; shares leap - Investing.com Australia
LEAP-012 Combination of Therapies Extends Progression-Free Survival in Intermediate-Stage Hepatocellular Carcinoma - The ASCO Post
Leap Therapeutics CEO to Present at Piper Sandler Healthcare Conference | LPTX Stock News - StockTitan
HC Wainwright Reaffirms Buy Rating for Leap Therapeutics (NASDAQ:LPTX) - Defense World
Microsoft's Azure Chips Promise AI Leap, Taking on Nvidia and AMD in Cloud Tech Race - Yahoo Finance
HCW Biologics Inc. (HCWB): A Strategic Leap with Worldwide Licensing Agreement Sends Stock Up Over 310% - BP Journal
Simplify Asset Management Inc. Acquires 425,626 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) - MarketBeat
Balyasny Asset Management L.P. Reduces Stake in Leap Therapeutics Inc - GuruFocus.com
Leap Therapeutics Reports Third Quarter 2024 Financial Results - citybiz
Leap Therapeutics Reports Wider Q3 Loss, Advances Cancer Drug Trials with $62.8M Cash | LPTX Stock News - StockTitan
Liquor, Wine, Beer: Which Comes With the Worst Lifestyle? - 69News WFMZ-TV
Sparked by FDA expansion, Sarepta's Elevidys takes another leap in sales - FiercePharma
Sermonix Pharmaceuticals’ Lasofoxifene Is Well Tolerated, - GlobeNewswire
DKN-01 With Tislelizumab and Chemotherapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma - The ASCO Post
Leap Therapeutics, Inc. (NASDAQ:LPTX) Sees Large Decline in Short Interest - MarketBeat
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Payment processor Finix secures $75m in Series C funding - Electronic Payments International
Dyno Therapeutics Forms New Strategic Partnership With Roche To Advance AAV Gene Therapy Vectors For Neurological Diseases - Business Wire
FDA clears Astellas' Vyloy as first claudin 18.2 cancer drug - pharmaphorum
Astellas nabs class-first FDA approval for CLDN18.2 gastric cancer med Vyloy - FiercePharma
Dow Jones notches new record, chip stocks leap higher - Yahoo Finance
Marshall Wace LLP Acquires New Stake in ChromaDex Co. (NASDAQ:CDXC) - Defense World
Profire Energy, Inc. (NASDAQ:PFIE) Shares Sold by Marshall Wace LLP - Defense World
Marshall Wace LLP Makes New Investment in Vivid Seats Inc. (NASDAQ:SEAT) - Defense World
SoFi's $2 Billion Leap: Golden Cross Sparks A Bullish Boom - Yahoo Finance
Startup company founded by Washington University scientists acquired by Eli Lilly – WashU Medicine - WashU Medicine
Venous Leg Ulcers Treatment Market value, Innovations Driving Market Evolution (2024-2036) - Third Eye News
Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients - The Malaysian Reserve
LPTXLeap Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Venous Leg Ulcers Treatment Market Growth, Size, Research Report and Forecast (2024-2034) - Talented India
Leap Therapeutics (NASDAQ:LPTX) Share Price Passes Below 50 Day Moving Average of $2.58 - MarketBeat
Biliary Tract Cancer Pipeline Analysis 2024: FDA Approvals - openPR
TSX Communication Services Capped Index (TTTS) QuotePress Release - The Globe and Mail
Alphamin Resources Corp. (CVE:AFM) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Simplify Asset Management Inc. Has $1.24 Million Stock Position in Leap Therapeutics, Inc. (NASDAQ:LPTX) - MarketBeat
Simplify Asset Management Inc. Buys 255,293 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) - Defense World
Meiji Yasuda Asset Management Co Ltd. Has $1.22 Million Stock Position in Hilton Worldwide Holdings Inc. (NYSE:HLT) - Defense World
Commonwealth Equity Services LLC Boosts Position in AllianzIM U.S. Large Cap Buffer10 Sep ETF (NYSEARCA:SEPT) - Defense World
Newmark Security (LON:NWT) Stock Price Crosses Above Two Hundred Day Moving Average of $91.75 - Defense World
How Analyst Ratings Affect Leap Therapeutics Inc Inc. (LPTX) Price Performance - The InvestChronicle
Advances in Sickle Cell Disease: New Gene Therapies and Management Strategies - Pharmacy Times
Leap Therapeutics Inc Stock (LPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
1.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):